Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gossamer Bio (GOSS) EBITDA: 2018-2024

Historic EBITDA for Gossamer Bio (GOSS) over the last 7 years, with Dec 2024 value amounting to -$55.0 million.

  • Gossamer Bio's EBITDA fell 48.36% to -$48.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$159.0 million, marking a year-over-year decrease of 117.09%. This contributed to the annual value of -$55.0 million for FY2024, which is 69.38% up from last year.
  • Per Gossamer Bio's latest filing, its EBITDA stood at -$55.0 million for FY2024, which was up 69.38% from -$179.6 million recorded in FY2023.
  • Gossamer Bio's 5-year EBITDA high stood at -$55.0 million for FY2024, and its period low was -$243.0 million during FY2020.
  • Moreover, its 3-year median value for EBITDA was -$179.6 million (2023), whereas its average is -$154.9 million.
  • Its EBITDA has fluctuated over the past 5 years, first tumbled by 35.02% in 2020, then spiked by 69.38% in 2024.
  • Gossamer Bio's EBITDA (Yearly) stood at -$243.0 million in 2020, then climbed by 3.48% to -$234.6 million in 2021, then grew by 1.94% to -$230.0 million in 2022, then increased by 21.92% to -$179.6 million in 2023, then soared by 69.38% to -$55.0 million in 2024.